Bain Capital seeded a new immunology platform that launched out of stealth as Beeline Medicines, built around five shelved Bristol Myers Squibb assets. The company surfaced with a Series A of $300 million and an initial program led by afimetoran for systemic lupus erythematosus, including an ongoing Phase 2 effort expected to complete in the second half of the year. Beeline’s pipeline also includes early efforts in atopic dermatitis and lupus, plus a once-daily TYK2 inhibitor program in plaque psoriasis positioned for additional development in rare immunological diseases. The company said it has preclinical candidates tied to IL-8 and IL-10 receptor biology. Leadership comes from an executive bench that includes veterans from SpringWorks Therapeutics, Nimbus Therapeutics, and OrbiMed. The startup plans a pivotal program after Phase 2 readouts, using its licensing approach to repurpose assets with existing early clinical context from BMS. For market observers, Beeline is another example of capital reallocation toward immunology licensing deals that convert “back-burner” assets into development programs with clear near-term milestones.